Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

FGI-106

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
FGI-106
Legal status
Legal status
Identifiers
  • N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC28H38N6
Molar mass458.654 g·mol−1
3D model (JSmol)
  • CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C
  • InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32)
  • Key:WJUPENLNVUCETH-UHFFFAOYSA-N

FGI-106 is a broad-spectrumantiviral drug developed as a potential treatment for enveloped RNA viruses, in particularviral hemorrhagic fevers from thebunyavirus,flavivirus andfilovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruseshantavirus,Rift Valley fever virus andCrimean-Congo hemorrhagic fever virus, the flavivirusdengue virus, and the filovirusesEbola virus andMarburg virus.[1][2][3][4][5]

See also

[edit]

References

[edit]
  1. ^Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, et al. (September 2009). "Development of a broad-spectrum antiviral with activity against Ebola virus".Antiviral Research.83 (3):245–51.doi:10.1016/j.antiviral.2009.06.001.PMID 19523489.
  2. ^Smith DR, Ogg M, Garrison A, Yunus A, Honko A, Johnson J, Olinger G, Hensley LE, Kinch MS (2010)."Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae".Virus Adaptation and Treatment: 9.doi:10.2147/VAAT.S6903.
  3. ^Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, et al. (April 2011)."Identification of a small-molecule entry inhibitor for filoviruses".Journal of Virology.85 (7):3106–19.doi:10.1128/JVI.01456-10.PMC 3067866.PMID 21270170.
  4. ^Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR, Nicastri E (March 2012)."Viral hemorrhagic fevers: advancing the level of treatment".BMC Medicine.10: 31.doi:10.1186/1741-7015-10-31.PMC 3325866.PMID 22458265.
  5. ^Picazo E, Giordanetto F (February 2015). "Small molecule inhibitors of ebola virus infection".Drug Discovery Today.20 (2):277–86.doi:10.1016/j.drudis.2014.12.010.PMID 25532798.
Ebolavirus
Outbreaks
Species
Drug candidates
Drugs
Notable people
Popular culture
Miscellaneous
Marburgvirus
Outbreaks
Species
Drug candidates
Popular culture
Miscellaneous
Cuevavirus
Species
Dianlovirus
Species
Striavirus
Species
Thamnovirus
Species
RNA virusantivirals (primarilyJ05, alsoS01AD andD06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5BRNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Stub icon

Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=FGI-106&oldid=1190246420"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp